Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
A Randomized Phase 2 Trial Of Paclitaxel, Carboplatin And Bevacizumab With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Bessemer, Alabama, United States, 35022
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35209
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35205
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35213
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35235
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 32511
- Pfizer Investigational Site
-
Mobile, Alabama, United States, 36607
- Pfizer Investigational Site
-
-
California
-
Fountain Valley, California, United States, 92708
- Pfizer Investigational Site
-
Los Angeles, California, United States, 90033
- Pfizer Investigational Site
-
-
Florida
-
Cocoa Beach, Florida, United States, 32931
- Pfizer Investigational Site
-
Merritt Island, Florida, United States, 32952
- Pfizer Investigational Site
-
Rockledge, Florida, United States, 32955
- Pfizer Investigational Site
-
Titusville, Florida, United States, 32796
- Pfizer Investigational Site
-
-
Georgia
-
Valdosta, Georgia, United States, 31602
- Pfizer Investigational Site
-
-
Illinois
-
Joliet, Illinois, United States, 60435
- Pfizer Investigational Site
-
Joliet, Illinois, United States, 60432
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Pfizer Investigational Site
-
-
North Carolina
-
Clinton, North Carolina, United States, 28382
- Pfizer Investigational Site
-
Goldsboro, North Carolina, United States, 27534
- Pfizer Investigational Site
-
Pollocksville, North Carolina, United States, 28573
- Pfizer Investigational Site
-
Wilson, North Carolina, United States, 27893
- Pfizer Investigational Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Pfizer Investigational Site
-
Knoxville, Tennessee, United States, 37934
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78705
- Pfizer Investigational Site
-
Austin, Texas, United States, 78745
- Pfizer Investigational Site
-
Austin, Texas, United States, 78759
- Pfizer Investigational Site
-
Austin, Texas, United States, 78758
- Pfizer Investigational Site
-
Georgetown, Texas, United States, 78626
- Pfizer Investigational Site
-
San Marcos, Texas, United States, 78666
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Advanced Stage IIIb with pleural effusion or Stage IV nonsquamous non-small cell lung cancer
- ECOG Performance Status 0-1
- Measurable disease per RECIST criteria
Exclusion Criteria:
- Squamous cell, small cell, or carcinoid lung cancer
- CNS metastasis
- Pre-existing autoimmune or antibody mediated disease
- Prior systemic treatment for NSCLC with chemo, immunotherapy, biologics, or investigation drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: B
Standard of care chemotherapy
|
paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
Other Names:
|
|
Experimental: A
Standard of care chemotherapy plus experimental intervention (PF-3512676)
|
carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free survival
Time Frame: 110 Events
|
110 Events
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall Survival
Time Frame: Time of death
|
Time of death
|
|
Time to Tumor Progression
Time Frame: End of treatment
|
End of treatment
|
|
Overall Objective Response Rate
Time Frame: Time of progressive disease
|
Time of progressive disease
|
|
Duration of Response
Time Frame: Time of progression
|
Time of progression
|
|
Overall safety profile
Time Frame: 28 days post treatment
|
28 days post treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Carboplatin
- Paclitaxel
- Bevacizumab
- Albumin-Bound Paclitaxel
Other Study ID Numbers
Other Study ID Numbers
- A8501003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.